



Bulletin from Artimplant AB's annual meeting of stockholders

Västra Frölunda, Sweden, May 4, 2007

Adoption of financial statements, disposition of result and discharge of directors and officers

The financial statements of 2006 were adopted. The annual meeting decided to set off the retained loss of SEK 55,263,000 against the premium reserve. The directors and officers of the Company were granted discharge.

Election of board members and auditor

Ingemar Kihlström was reelected as chairman of the board and Lennart Ribohn as well as Dick Söderberg were reelected as ordinary board members. Anna Malm Bernsten and Wenche Rolfsen were elected as new ordinary board members. Ernst & Young with Bertel Enlund as responsible partner was elected for the upcoming three years.

Adoption of fees

The annual meeting decided that the fee to the board of directors shall be SEK 260,000 to the chairman and 130,000 to ordinary board members. The audit fee will the upcoming three years be SEK 150,000 per year.

Nomination committee

The annual meeting decided that the nomination committee before the annual meeting of 2007, planned to May 2008, shall be appointed by representatives from the three largest stockholders as of September 30, 2007.

Principles for remuneration to senior management

The annual meeting adopted the principles for remuneration to senior management as suggested by the board of directors.

Employee stock options

The annual meeting decided to adopt the suggested incentive program.

All above mentioned decisions were taken unanimously.

Artimplant AB (publ)

The Board of Directors

For additional information, please contact:

Ingemar Kihlström, Chairman, phone +46 (0)733-82 11 02

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.